当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-02-01 , DOI: 10.1016/s2213-2600(18)30012-2
Elianne J L E Vrijlandt , Georges El Azzi , Mark Vandewalker , Ned Rupp , Thomas Harper , LeRoy Graham , Stanley J Szefler , Petra Moroni-Zentgraf , Ashish Sharma , Sebastian D Vulcu , Ralf Sigmund , Bo Chawes , Michael Engel , Hans Bisgaard

Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1-5 years with persistent asthmatic symptoms.

中文翻译:

噻托铵在1-5岁持续哮喘症状中的安全性和有效性:一项随机,双盲,安慰剂对照试验。

很少有研究评估潜在哮喘药物对5岁以下儿童的安全性和有效性。我们以描述性的方式评估了噻托溴铵(一种长效抗胆碱药)在1-5岁持续存在哮喘症状的儿童中的安全性和有效性。
更新日期:2018-01-26
down
wechat
bug